Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status: Window of treatment

Drugs of Today

Volumn 38, Issue 5, 2002, Pages 365-376

  Farkas, Eszter ^a   De Wilde, Martijn C ^a   Kiliaan, Amanda J ^a   Luiten, Paul G M ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BUFLOMEDIL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DIHYDROPYRIDINE DERIVATIVE; HEMORHEOLOGIC AGENT; HEPTYLSTIGMINE TARTRATE; LINOPIRDINE; NIMODIPINE; PENTOXIFYLLINE; PHYSOSTIGMINE; POLYUNSATURATED FATTY ACID; SPASMOLYTIC AGENT; TACRINE; UNCLASSIFIED DRUG; VASOACTIVE AGENT; ANTICOAGULANT AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN BLOOD FLOW; BRAIN PERFUSION; COGNITION; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; GLIOSIS; HIPPOCAMPUS; HUMAN; HYPERTENSION; LEARNING; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARIETAL LOBE; RAT; REVIEW; SPATIAL MEMORY; VASCULAR DISEASE; ANIMAL; BRAIN; BRAIN ISCHEMIA; DIET; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; VASCULAR SMOOTH MUSCLE;

ANIMAL; ANTICOAGULANTS; BRAIN; BRAIN ISCHEMIA; CHOLINERGIC AGENTS; COGNITION; COGNITION DISORDERS; DIET; HUMAN; MUSCLE, SMOOTH, VASCULAR; VASODILATOR AGENTS; ANIMALS; HUMANS;

EID: 0036266871     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.5.677137     Document Type: Review

References (79)

1. Cerebral microvascular pathology in aging and Alzheimer's disease
2. Overlap between pathology of Alzheimer disease and vascular dementia
3. Vascular factors and Alzheimer disease
4. Assessment of demented patients by dynamic SPECT of inhaled xenon-133
5. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases
6. Cerebral blood flow and histopathological changes following permanent bilateral carotid artery ligation in Wistar rats
7. Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats
8. Stimulation of the nucleus basalis of Meynert increases cerebral cortical blood flow in rats
9. Autoradiographic distribution of cerebral blood flow increases elicited by stimulation of the nucleus basalis magnocellularis in the unanesthetized rat
10. Cholinergic basal forebrain neurons project to cortical microvessels in the rat: Electron microscopic study with anterogradely transported Phaseolus vulgaris leucoagglutinin and choline acetyltransferase immunocytochemistry
11. Ultrastructural localization of cholinergic muscarinic receptors in rat brain cortical capillaries
12. Neurochemical stimulation of the rat substantia innominata increases cerebral blood flow (but not glucose use) through the parallel activation of cholinergic and non-cholinergic pathways
13. Functional acetylcholine muscarinic receptor subtypes in human brain microcirculation: Identification and cellular localization
14. Differentiated cerebrovascular effects of physostigmine and tacrine in cortical areas deafferented from the nucleus basalis magnocellularis suggest involvement of basalocortical projections to microvessels
15. Linopirdine. A depolarization-activated releaser of transmitters for treatment of dementia
16. Cholinesterase inhibitors for Alzheimer's disease
17. PET studies and cholinergic therapy in Alzheimer's disease
18. Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease
19. Response to tacrine in patients with dementia of the Alzheimer's type: Cerebral perfusion change is related to change in mental status
20. Long-term tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities
21. Age-related impairment of coupling mechanism between neuronal activation and functional cerebral blood flow response was restored by cholinesterase inhibition: PET study with microdialysis in the awake monkey brain
22. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease
23. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease
24. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG
25. Physostigmine in Alzheimer's disease: Effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography
26. Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients
27. Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex
28. Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats
29. The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease
30. Sumatriptan elicits both constriction and dilation in human and bovine brain intracortical arterioles
31. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy
32. Effect of pentoxifylline on cerebral blood flow in patients with chronic cerebrovascular disease
33. Pentoxifylline increases cerebral blood flow in patients with cerebrovascular disease
34. Effect of propentofylline and pentoxifylline on cerebral blood flow using 1231-IMP SPECT in patients with cerebral arteriosclerosis
35. Comparative studies of drotaverine-acephyllinate (Depogen) and pentoxifylline (Trental)
36. Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects
37. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation
38. Inhibition of platelet adhesion to collagen by cGMP-elevating agents
39. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets
40. Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases
41. The pharmacological effects of buflomedil in patients with multicerebral infarcts dementia: An open, preliminary assessment
42. Effect of long-term administration of buflomedil on regional cerebral blood flow in chronic cerebral infarction
43. Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin
44. State of the art-treatment of peripheral occlusive arterial disease (POAD) with drugs vs. vascular reconstruction or amputation
45. Buflomedil for intermittent claudication (Cochrane Review)
46. Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders
47. The pharmacological properties of lipophilic calcium antagonists
48. Pharmacological basis for the use of nimodipine in central nervous system disorders
49. Functional aspects of calcium-channel modulation
50. Cerebrovascular, neuronal, and behavioral effects of long-term Ca2+ channel blockade in aging normotensive and hypertensive rat strains
51. Effects of nifedipine and nicardipine on regional cerebral blood flow distribution in patients with arterial hypertension
52. Nilvadipine increases cerebral blood flow in elderly hypertensives: Comparison with nifedipine
53. The effect of nilvadipine, a dihydropyridine type calcium channel blocker, on local cerebral blood flow in rats
54. Effects of nilvadipine on regional cerebral blood flow and skin blood flow in anesthetized cats
55. Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-related disorders
56. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease
57. Microvascular changes in aged rat forebrain. Effects of chronic nimodipine treatment
58. Calcium antagonists decrease capillary wall damage in aging hypertensive rat brain
59. Similar ultrastructural breakdown of cerebrocortical capillaries in Alzheimer's disease, Parkinson's disease and experimental hypertension. What is the functional link?
60. Cerebral hypoperfusion yields capillary damage in hippocampus CA1 that correlates to spatial memory impairment
61. Nimodipine: Cognition, aging, and degeneration
62. Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine, influence of aging and developmental drug treatment
63. Essential fatty acids and the brain: Possible health implications
64. Fatty acid intake and the risk of dementia and cognitive decline: A review of clinical and epidemiological studies
65. Dietary fat intake and the risk of incident dementia in the Rotterdam Study
66. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases
67. Dietary fats and blood pressure
68. Importance of n-3 fatty acids in health and disease
69. Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: A PET study in conscious monkeys
70. The effect of n-3 polyunsaturated fatty acid-rich diets on cognitive and cerebrovascular parameters in chronic cerebral hypoperfusion
71. Effects of eicosapentaenoic acid and docosahexaenoic acid on plasma membrane fluidity of aortic endothelial cells
72. The hypotensive effect of docosahexaenoic acid is associated with the enhanced release of ATP from the caudal artery of aged rats
73. Fatty acid modulation of endothelial activation
74. Correlation between level of (n-3) polyunsaturated fatty acids in brain phospholipids and learning ability in rats. A multiple generation study
75. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats
76. Modulation of learning, pain thresholds, and thermoregulation in the rat by preparations of free purified alphalinolenic and linoleic acids: Determination of the optimal omega 3-to-omega 6 ratio
77. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats
78. Dietary long chain PUFAs differentially affect hippocampal muscarinic 1 and serotonergic 1A receptors in experimental cerebral hypoperfusion
79. Ameliorative effect of tacrine on spatial memory deficit in chronic two-vessel occluded rats is reversible and mediated by muscarinic M1 receptor stimulation